Ligand Pharmaceuticals (LGND) Depreciation and Depletion (2012 - 2026)

Ligand Pharmaceuticals has disclosed Depreciation and Depletion across 8 years of filings, most recently posting $119000.0 for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $119000.0, down 76.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $606000.0 (down 72.87% YoY), and the FY2025 annual result was $1.0 million, down 56.52% from the prior year.
• Depreciation and Depletion came in at $119000.0 for Q1 2026 at Ligand Pharmaceuticals, up from $51000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $736000.0 in Q3 2024 to a low of $51000.0 in Q4 2025.
• The 3-year median for Depreciation and Depletion is $389000.0 (2024), against an average of $379888.9.
• Peak annual rise in Depreciation and Depletion reached 11.4% in 2025, while the deepest fall reached 86.89% in 2025.
• Ligand Pharmaceuticals' Depreciation and Depletion stood at $389000.0 in 2024, then slumped by 86.89% to $51000.0 in 2025, then jumped by 133.33% to $119000.0 in 2026.
• The last three Depreciation and Depletion figures came in at $119000.0 (Q1 2026), $51000.0 (Q4 2025), and $172000.0 (Q3 2025), per Business Quant data.